As discussions around Artificial Intelligence/Machine Learning continue to expand with policy makers, MDMA has formed an Artificial Intelligence working group to address these issues and discuss priorities. With FDA authorizing the first medical device with AI in 1995 and hundreds more since, it is important that any new potential requirements are not duplicative or run counter to FDA requirements. There are also issues around reimbursement, assurance labs, and data privacy/ownership that this group explores.